Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgen-deprivation therapy for prostate cancer
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Purpose Hot flash (HF) is a common side effect in prostate cancer patient undergoing androgen-deprivation therapy (ADT). In this study, we evaluated the efficacy of paroxetine (selective serotonin reuptake inhibitors (SSRIs)) for HF. Patients and methods In total, 10 men with prostate cancer under ADH who were suffering with HF entered this study. Self-report questionnaire was used for the evaluation. Results The average rating for HF frequency decreased (P=0.009) and HF severity decreased (P=0.0332) also, reported QOL score increased (P=0.0218). Conclusion These preliminary data suggest that low dose (10 mg/day) of antidepressant paroxetine can be helpful in the treatment of HFs in patients under ADT for prostate cancer. Further controlled studies are needed to more fully evaluate the efficacy of the SSRIs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In men, hot flashes are caused by many of the hormonal therapies, including orchiectomy [48].”
From Prostate cancer: Psychosocial implications and management (2008) · cites this paper as [48]
Citations
Cites
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
Textbook of psychopharmacology
Edwards, G. (1975) · Nature · doi:10.1038/258648b0 · Cited by 585
Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes
Loprinzi, C. L., Sloan, J. A., Perez, E. A., Quella, S. K., Stella, P. J., Mailliard, J. A., Halyard, M. Y., Pruthi, S., Novotny, P. J., & Rummans, T. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1578 · Cited by 473
The Effect of Dietary Soy Supplementation on Hot Flushes
Albertazzi, P. (1998) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(97)00597-8 · Cited by 443
Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.
Barton, D. L., Loprinzi, C. L., Quella, S. K., Sloan, J. A., Veeder, M. H., Egner, J. R., Fidler, P., Stella, P. J., Swan, D. K., Vaught, N. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.495 · Cited by 403
Pandya, K. J., Morrow, G. R., Roscoe, J. A., Zhao, H., Hickok, J. T., Pajon, E., Sweeney, T. J., Banerjee, T. K., & Flynn, P. J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67215-7 · Cited by 333
Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.
Goldberg, R. M., Loprinzi, C. L., O'Fallon, J. R., Veeder, M. H., Miser, A. W., Mailliard, J. A., Michalak, J. C., Dose, A. M., Rowland, K. M., & Burnham, N. L. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.155 · Cited by 292
Pathophysiology and Treatment of Hot Flashes
Shanafelt, T. D., Barton, D. L., Adjei, A. A., & Loprinzi, C. L. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.11.1207 · Cited by 273
Stearns, V., Isaacs, C., Rowland, J., Crawford, J., Ellis, M. J., Kramer, R., Lawrence, W., Hanfelt, J. J., & Hayes, D. F. (2000) · Annals of Oncology · doi:10.1023/a:1008382706068 · Cited by 224
Hot flashes: phenomenology, quality of life, and search for treatment options
Kronenberg, F. (1994) · Experimental Gerontology · doi:10.1016/0531-5565(94)90012-4 · Cited by 217
Cited by
Carter, J., Lacchetti, C., Andersen, B. L., Barton, D. L., Bolte, S., Damast, S., Diefenbach, M. A., DuHamel, K., Florendo, J., Ganz, P. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.8995 · Cited by 359
Irani, J., Salomon, L., Oba, R., Bouchard, P., & Mottet, N. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70338-9 · Cited by 159
Prostate cancer: Psychosocial implications and management
Roth, A. J., Weinberger, M. I., & Nelson, C. J. (2008) · Future Oncology · doi:10.2217/14796694.4.4.561 · Cited by 113
Depression and prostate cancer: A focused review for the clinician
Fervaha, G., Izard, J., Tripp, D. A., Rajan, S., Leong, D. P., & Siemens, D. R. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.12.020 · Cited by 103
Interventions to Address Sexual Problems in People with Cancer
Barbera, L. C., Zwaal, C., Elterman, D., McPherson, K., Wolfman, W., Katz, A., & Matthew, A. (2017) · Current Oncology · doi:10.3747/co.24.3583 · Cited by 81
Managing hot flushes in men after prostate cancer—A systematic review
Frisk, J. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.10.017 · Cited by 67
Gonzalez, B. D., Small, B. J., Cases, M. G., Williams, N. L., Fishman, M. N., Jacobsen, P. B., & Jim, H. S. L. (2018) · Cancer · doi:10.1002/cncr.31024 · Cited by 66
Klaassen, Z. W. A., Arora, K., Wilson, S. N., King, S. A., Madi, R., Neal, D. E., Kurdyak, P. A., Kulkarni, G. S., Lewis, R. W., & Terris, M. K. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.09.007 · Cited by 77
Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes
Daneshmand, S., & Ahmadi, H. (2014) · Patient Related Outcome Measures · doi:10.2147/prom.s52788 · Cited by 61
Complications of androgen deprivation therapy in prostate cancer
Schwandt, A., & Garcia, J. A. (2009) · Current Opinion in Urology · doi:10.1097/mou.0b013e32832a082c · Cited by 49
Androgen deprivation therapy-associated vasomotor symptoms
Jones, J. M., Kohli, M., & Loprinzi, C. L. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.101 · Cited by 47
Management of the side effects of androgen deprivation therapy in men with prostate cancer
Flaig, T. W., & Glodé, L. M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.16.2829 · Cited by 30
Alwhaibi, A. M., Alsanea, S., Almadi, B., Alsabhan, J. F., & Alosaimi, F. D. (2022) · The Aging Male · doi:10.1080/13685538.2022.2053954 · Cited by 26
Management of Hormone Deprivation Symptoms After Cancer
Faubion, S. S., Loprinzi, C. L., & Ruddy, K. J. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.04.009 · Cited by 16
Pharmacotherapy of Depression in People with Cancer
Grassi, L. G., Nanni, M. G., Uchitomi, Y., & Riba, M. (2010) · Wiley eBooks · doi:10.1002/9780470972533.ch7 · Cited by 19
Alekshun, T. J., & Patterson, S. G. (2006) · Supportive Cancer Therapy · doi:10.3816/sct.2006.n.029 · Cited by 11
A Review of Hot Flash Management in Patients With Prostate Cancer
Lin, K. L., Talmor, B., Crumbaker, M., & Joshua, A. M. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf302 · Cited by 10
Physiology and Endocrinology of Hot Flashes in Prostate Cancer
Engstrom, C., & Kasper, C. (2007) · American Journal of Men's Health · doi:10.1177/1557988306294162 · Cited by 8
Lan, N. T., Duc, T. M., & Anh, P. H. (2024) · Specialty journal of Pharmacognosy Phytochemistry and Biotechnology · doi:10.51847/z0yjxkddqs · Cited by 5
Treatment of Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
Schaldemose, E. L., Poulsen, M. H., Nørby, B., & Madsen, C. V. (2026) · The Prostate · doi:10.1002/pros.70229 · Cited by 1
Die antiandrogene Therapie aus urologischer Sicht
Korda, J. B., & Sommer, F. O. (2010) · Forensische Psychiatrie Psychologie Kriminologie · doi:10.1007/s11757-010-0054-7 · Cited by 1
The Utility of Low‐Dose Antidepressants
Zilberman, M. L., Gorenstein, C., & Gentil, V. (2010) · Wiley eBooks · doi:10.1002/9780470749180.ch9 · Cited by 2
Les effets secondaires de l’hormonothérapie et leur gestion
Hennequin, C., Mongiat-Artus, P., Quéro, L., Pouessel, D., & Culine, S. (2012) · ONCOLOGIE · doi:10.1007/s10269-012-2124-2
Tratamiento del cáncer de próstata
González, A. B. (2010)
Radiation with Hormonal Therapy
Baker, B. R., Mohiuddin, J. J., & Chen, R. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800077-9.00043-8
Approaches to Specific Cancers
Koh, K. B. (2018) · Springer eBooks · doi:10.1007/978-3-030-02783-4_25
Koh, K. B. (2026) · Springer eBooks · doi:10.1007/978-3-032-11214-9_17
The HPA axis and GABA-Glutamate Systems as Potential Antidepressant Targets in Prostate Cancer
Sharpley, C. F. (2011) · The Open Prostate Cancer Journal · doi:10.2174/1876822901104010001 · Cited by 1
Metadata
- Authors
- Naoe, M., Ogawa, Y., Shichijo, T., Fuji, K., Fukagai, T., & Yoshida, H.
- Affiliations
- SHOWA Medical University (JP)
- Corresponding author
- Naoe, M
- Venue
- Prostate Cancer and Prostatic Diseases
- Published
- 2006-06-20
- Volume
- 9
- Issue
- 3
- Pages
- 275-278
- ISSN
- 1365-7852 (ISSN-L)
- 1476-5608
- OpenAlex
- W1988818828
- Cited by
- 28
- References
- 21
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2022: 1 · 2019: 1 · 2018: 1 · 2017: 4 · 2016: 1 · 2015: 1 · 2014: 1 · 2012: 2
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Prostate Cancer and Prostatic Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Keywords
- paroxetine, selective serotonin reuptake inhibitors, androgen deprivation therapy, prostate cancer, menopausal symptoms, quality of life, antidepressant efficacy
- MeSH terms
- Aged, Aged, 80 and over, Androgen Antagonists, Antidepressive Agents, Carcinoma, Dose-Response Relationship, Drug, Humans, Male, Middle Aged, Pilot Projects, Prostatic Neoplasms, Selective Serotonin Reuptake Inhibitors, Paroxetine, Hot Flashes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.